Deciphera Pharmaceuticals, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Deciphera Pharmaceuticals, Inc. had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $23.37 million as of 2023-12-31, per its 10-K filed 2024-02-07.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2024-02-07
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $23.37M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $20.13M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $15.70M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.93M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2023-12-31 | $23.37M 10-K · filed 2024-02-07 |
| 2022-12-31 | $20.13M 10-K · filed 2024-02-07 |
| 2021-12-31 | $15.70M 10-K · filed 2023-02-07 |
| 2020-12-31 | $8.93M 10-K · filed 2022-02-08 |
| 2019-12-31 | $5.54M 10-K · filed 2021-02-09 |
| 2018-12-31 | $4.68M 10-K · filed 2020-03-09 |
| 2017-12-31 | $2.37M 10-K · filed 2019-03-14 |